Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The use of fluoroquinolone in children

소아에서 fluoroquinolone 사용

  • Hur, Jae Kyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 허재균 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2008.08.28
  • Accepted : 2008.09.05
  • Published : 2008.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

The fluoroquinolones are an important group of antibiotics widely used in the treatment of various infectious diseases in adults, as a result of an excellent spectrum of activity, good tissue penetration and convenient ways of administration. In recent decades, there has been extensive development, clinical investigation, licensure and use of fluoroquinolone antibiotics. However, the use of fluoroquinolones in children has been limited because of their potential to induce arthropathy in juvenile animals. Despite class label warnings against use in children, prescriptions for quinolone antibiotics to treat infections in children have become increasingly prevalent. The main use of fluoroquinolones in pediatrics should be, understandably, in serious life-threatening infections for which other antibiotics therapies are not effective or available. While most of the published studies failed to detect an increased rate of articular adverse effects in children treated with fluoroquinolones, an increase in the use of these compounds, particularly in community-acquired lower respiratory infections, could accelerate the emergence of multidrug-resistant (including fluoroquinolone) pneumococcal strains. This review will discus the main issues related to the use of fluoroquinolones in children, the major problems of resistance developing among these compounds, with special emphasis on the potential side effects and skilled use of these alternative potent drugs in pediatric infection.

Keywords

References

  1. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87 https://doi.org/10.1016/0041-008X(79)90020-6
  2. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988;10(Suppl 1):141-6 https://doi.org/10.1093/clinids/10.Supplement_1.S141
  3. Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989;87(Suppl 5A):37-9 https://doi.org/10.1016/S0002-9343(89)80927-1
  4. Hooper DC, Rubinstein E. Quinolone Antimicrobial Agents. 3rd ed. Washington, DC: ASM Press; 2003
  5. Capparelli EV, Reed MD, Bradley JS, Keams GL, Jacohs RF, Damie BD et al. Pharmacokinetics of gatifloxacin in infants and children. Antimicrob Agents Chemother 2005; 49:1106-12 https://doi.org/10.1128/AAC.49.3.1106-1112.2005
  6. Leibovitz E, Dagan R, Blumer J. Pharmacokinetics of levofloxacin in plasma and middle ear fluid of infants and young children (page 1, abstractA-6). 43th Interscience. Conference on Antimicrobial Agents and Chemotherapy; 30 October-2 November; Washington, DC. 2004
  7. Ho PL, Que TL, Chiu SS, Yung RW, Ng TK, Tsang DN et al. Fluoroquinolone and other antimicrobial resistance. Emerg Infect Dis 2004;10:1250-7 https://doi.org/10.3201/eid1007.030612
  8. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial Resistance among Streptococcus pneumoniae in the United States: Have We Begun to Turn the Corner on Resistance to Certain Antimicrobial Classes? Clin Infect Dis 2005;41:139-48 https://doi.org/10.1086/430906
  9. Reinert RR, Reinert S, Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Strep pneumo in eight European countries. Antimicrob Agents Chemother 2005;49:2903-13 https://doi.org/10.1128/AAC.49.7.2903-2913.2005
  10. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, Azavedo JCS, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococal pneumonia. N Engl J Med 2002;346:747-50 https://doi.org/10.1056/NEJMoa012122
  11. Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, et al. The battle against emerging antibiotic resistance: Should Fluoroquinolones Be Used to Treat Children? Clin Infect Dis 2002;35:721-7 https://doi.org/10.1086/341900
  12. Schaad UB, Stoupis C, Wedgwood J, Tsch-aeppeler H, Vock P. Clinical, radiologic and mag-netic resonance monitoring for skeletal toxi-city in pediatric patients with cystic fibrosis re-ceiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991;10:723-9
  13. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthopathy in animals versus children. Clin Infect Dis 1997;25: 1196-204 https://doi.org/10.1086/516119
  14. Chalumeau M, Tonnelier S, D'Athis P, Treluyer JM, Gendrel D, Breart G, et al. Fluoroquinolone safety in pediatric patients: a prospective, multi-center, comparative cohort study in France. Pediatrics 2003;111(6 Pt 1):e714-9 https://doi.org/10.1542/peds.111.6.e714
  15. Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, Agakidis C, Nikolaides N, Sarafidis K et al. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J 2004;23:34-9
  16. Hampel B, Hullmann R, Schmidt H. Ciproflox-acin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997;16:127-9 https://doi.org/10.1097/00006454-199701000-00036
  17. Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community community? The Lancet In-fectious Diseases 2003;3:537-46 https://doi.org/10.1016/S1473-3099(03)00736-9
  18. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intra-venous ceftriaxone administered in an out-patient setting for fever and neutropenia in low-risk pe-diatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000;34:87-91 https://doi.org/10.1002/(SICI)1096-911X(200002)34:2<87::AID-MPO2>3.0.CO;2-F
  19. Thaver D, Zaidi AK, Critchley J, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2005:CD004530
  20. Moulin F, Sauve-Martin H, Marc E, Lorrot MM, Soulier M, Ravilly S, et al. Ciprofloxacin after clinical failure of betalactam antibiotics in chil-dren with salmonellosis. Arch Pediatr 2003;10:608-14 https://doi.org/10.1016/S0929-693X(03)00281-1
  21. Vinh H, Duong NM, Phuong LT, Truong NT, Bay PV, Wain J, et al. Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children. Ann Trop Paediatr 2005;25:17-22 https://doi.org/10.1179/146532805X23308
  22. Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2000;19:1060-7 https://doi.org/10.1097/00006454-200011000-00006
  23. Guerin PJ, Brasher C, Baron E, Mic D, Grimont F, Ryan M, et al. Case management of a multi-drug-resistant Shigella dysenteriae sero-type 1 out-break in a crisis context in Sierra Leone, 1999-2000. Trans R Soc Trop Med Hyg 2004; 98:635-43 https://doi.org/10.1016/j.trstmh.2004.01.005
  24. Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect Dis 2003;3:537-46 https://doi.org/10.1016/S1473-3099(03)00736-9
  25. Cizman M, Orazem A, Kriza-Hergouth V, Kolman J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections. J Antimicrob Chemother 2001;47:502-3 https://doi.org/10.1093/jac/47.4.502
  26. Pichichero ME, Arguedas A, Dagan R, Sher L, Saez-Llorens X, Hamed K, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis J 2005;41: 470-8. https://doi.org/10.1086/431584
  27. Noel GJ, Leibovitz E, Dagan R. Levofloxacin therapy for infants and young children with persistent or recurrent acute otitis media (page 267, abstract G-2081). 43th Interscience Conference on Antimicrobial Agents and Chemotherapy; 30 October-2 November. 2004
  28. Sabella C. Management of otorrhea in infants and children. Pediatr Infect Dis J 2000;19:1007-8 https://doi.org/10.1097/00006454-200010000-00014
  29. Krcmery V Jr, Filka J, Uher J, Kurak H, Sagat T, Tuharsky J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999;35:75-80 https://doi.org/10.1016/S0732-8893(99)00052-8

Cited by

  1. Antibiotic Sensitivity Patterns in Children with Urinary Tract Infection: Retrospective Study Over 8 Years in a Single Center vol.23, pp.1, 2008, https://doi.org/10.3339/jkspn.2019.23.1.22